Antiadenovirus activities of several classes of nucleoside and nucleotide analogues.
The absence of any formally licensed antiadenovirus drugs and the increasing incidence of life-threatening adenovirus infections in immunosuppressed patients warrant the development of effective antiadenovirus compounds. A detailed study was performed on the antiadenovirus activities of several classes of nucleoside and nucleotide analogues in human embryonic lung fibroblast cells. The antiadenovirus activities were evaluated by three methods, viz., evaluating the adenoviral cytopathic effect, monitoring cell viability by a colorimetric assay, and real-time PCR quantitation of viral DNA as a direct parameter for virus replication. The most active and selective compounds were the acyclic nucleoside phosphonate analogues cidofovir, its adenine analogue (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA], and the new derivative (S)-2,4-diamino-6-[3-hydroxy-2-(phosphonomethoxy)propoxy]pyrimidine [(S)-HPMPO-DAPy]; the N7-substituted acyclic derivative 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine (S-2242); and the 2',3'-dideoxynucleoside analogues zalcitabine and alovudine. No antiadenovirus activity was observed for the antiviral drugs ribavirin, foscarnet, acyclovir, penciclovir, and brivudin, while ganciclovir displayed modest activity. However, in human osteosarcoma cells transfected with herpes simplex virus thymidine kinase, ganciclovir demonstrated highly potent antiadenovirus activity, suggesting that the efficacy of ganciclovir against adenovirus is limited by inefficient phosphorylation in adenovirus-infected cells, rather than by insufficient inhibition at the viral DNA polymerase level. Collectively, our antiviral data show that the adenovirus DNA polymerase exhibits sensitivity to a relatively broad spectrum of inhibitors and should be studied further as an antiviral target in antiadenovirus drug development programs.
Naesens
L
L
Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. lieve.naesens@rega.kuleuven.ac.be
Lenaerts
L
L
Andrei
G
G
Snoeck
R
R
Van Beers
D
D
Holy
Antonin
A
Balzarini
Jan
J
De Clercq
Erik
E
D000256:Adenoviridae / Q000187:drug effects*; D000998:Antiviral Agents / Q000494:pharmacology*; D015774:Ganciclovir / Q000494:pharmacology; D006801:Humans; D009705:Nucleosides / Q000494:pharmacology*; D009711:Nucleotides / Q000494:pharmacology*; D016133:Polymerase Chain Reaction; D013937:Thymidine Kinase / Q000032:analysis
D000998:Antiviral Agents; D009705:Nucleosides; D009711:Nucleotides; D013937:Thymidine Kinase; D015774:Ganciclovir
Antimicrob Agents Chemother. 2001 Jan;45(1):84-7
11120949
Antiviral Res. 1998 Dec;40(1-2):45-51
9864045
Bone Marrow Transplant. 2001 Mar;27(6):621-6
11319592
Biol Blood Marrow Transplant. 2001;7(7):388-94
11529489
Antiviral Res. 2001 Dec;52(3):281-8
11675145
J Virol Methods. 2002 Feb;100(1-2):1-16
11742648
J Med Chem. 2002 Apr 25;45(9):1918-29
11960502
Ophthalmology. 2002 May;109(5):845-50
11986086
Pediatrics. 2002 Jul;110(1 Pt 1):e9
12093990
Lancet Infect Dis. 2003 Feb;3(2):79-86
12560192
Bone Marrow Transplant. 2003 Mar;31(6):481-6
12665844
Biol Blood Marrow Transplant. 2003 May;9(5):341-52
12766884
Cancer Gene Ther. 2003 Oct;10(10):791-802
14502232
Curr Gene Ther. 2003 Dec;3(6):527-43
14683450
Clin Infect Dis. 2004 Jun 1;38(11):1521-5
15156436
Biochemistry. 1981 Apr 28;20(9):2628-32
7236628
Antimicrob Agents Chemother. 1987 Feb;31(2):337-9
3566256
J Infect Dis. 1991 Feb;163(2):270-5
1846389
Invest Ophthalmol Vis Sci. 1994 Nov;35(12):4135-43
7960596
Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603
7526782
Cornea. 1994 Sep;13(5):435-9
7995068
Eur J Clin Microbiol Infect Dis. 1995 Apr;14(4):318-29
7649195
N Engl J Med. 1996 Sep 5;335(10):721-9
8786764
Antiviral Res. 1997 May;34(3):113-9
9191018
Mol Pharmacol. 1998 Jan;53(1):157-65
9443944
Antimicrob Agents Chemother. 1998 Jul;42(7):1666-70
9661001
J Virol. 1998 Dec;72(12):9535-43
9811686
Clin Infect Dis. 2001 May 1;32(9):1290-7
11303263